{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:15Z","timestamp":1787019495865,"version":"build-2736575974"},"reference-count":233,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"DOI":"10.1182\/asheducation-2015.1.529","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:23:25Z","timestamp":1473938605000},"page":"529-544","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1182","volume":"2015","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111703545845100_B1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"2019111703545845100_B2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL; and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2019111703545845100_B3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and s\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111703545845100_B4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidulich","year":"2009","journal-title":"Int J Dermatol"},{"key":"2019111703545845100_B5","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"2019111703545845100_B6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2019111703545845100_B7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1995.01690210033005","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the S\u00e9zary Syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B10","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"2019111703545845100_B12","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: a review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"2019111703545845100_B13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.seminoncol.2007.11.006","article-title":"Mycosis Fungoides: pathophysiology and emerging therapies","volume":"34","author":"Duvic","year":"2007","journal-title":"Semin Oncol"},{"key":"2019111703545845100_B14","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/j.seminoncol.2007.11.006","article-title":"Mycosis fungoides: pathophysiology and emerging therapies","volume":"34","author":"Duvic","year":"2007","journal-title":"Semin Oncol"},{"key":"2019111703545845100_B15","first-page":"33","article-title":"Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies: review","volume":"21","author":"Duvic","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"2019111703545845100_B16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2015.02.027","article-title":"Advanced-stage mycosis fungoides and S\u00e9zary syndrome: survival and response to treatment","volume":"15","author":"Alberti-Violetti","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111703545845100_B17","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B18","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long term outcomes of 1263 patients with Mycosis fungoides and Sezary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"2019111703545845100_B21","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"2019111703545845100_B22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.6004\/jnccn.2008.0030","article-title":"Non-Hodgkin's lymphomas","volume":"6","author":"Zelenetz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111703545845100_B23","first-page":"55","volume-title":"T-cell Malignancies: Recent Developments and Novel Therapeutic Approaches","author":"Duvic","year":"2010"},{"key":"2019111703545845100_B24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B25","first-page":"165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"2003","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2019111703545845100_B27","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1067\/mjd.2000.107808","article-title":"Immunomodulatory and pharmacologic properties of imiquimod","volume":"43","author":"Sauder","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703545845100_B29","first-page":"691","article-title":"Electron beam therapy for mycosis fungoides: the Stanford University experience","volume":"63","author":"Hoppe","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2019111703545845100_B30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0360-3016(83)90258-4","article-title":"Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors","volume":"9","author":"Tadros","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111703545845100_B31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19810301)47:5<870::AID-CNCR2820470510>3.0.CO;2-R","article-title":"Once weekly total-skin electron beam therapy for mycosis fungoides: 7 years' experience","volume":"47","author":"Nisce","year":"1981","journal-title":"Cancer"},{"key":"2019111703545845100_B32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111703545845100_B34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archderm.1978.01640130027008","article-title":"Radiation dermatitis following electron beam therapy: an evaluation of patients ten years after total skin irradiation for mycosis fungoides","volume":"114","author":"Price","year":"1978","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B36","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J Invest Dermatol"},{"key":"2019111703545845100_B38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","article-title":"IL-12 reverses cytokine and immune abnormalities in S\u00e9zary syndrome","volume":"154","author":"Rook","year":"1995","journal-title":"J Immunol"},{"key":"2019111703545845100_B40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"2019111703545845100_B41","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1158\/0008-5472.CAN-04-1129","article-title":"Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids","volume":"64","author":"Mrass","year":"2004","journal-title":"Cancer Res"},{"key":"2019111703545845100_B42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and S\u00e9zary syndrome: a comparison of isotretinoin and etretinate: a study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"2019111703545845100_B43","first-page":"514","article-title":"Bexarotene ligand pharmaceuticals","volume":"1","author":"Hurst","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"key":"2019111703545845100_B44","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B45","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for the treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1396-0296.2003.01644.x","article-title":"Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma","volume":"16","author":"Zhang","year":"2003","journal-title":"Dermatol Ther"},{"key":"2019111703545845100_B47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/0001555564563566","article-title":"13-cis-retinoic acid effective in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group","volume":"64","author":"Thomsen","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"2019111703545845100_B48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2133.1983.tb03991.x","article-title":"Treatment of cutaneous lymphoma with etretinate","volume":"109","author":"Claudy","year":"1983","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B50","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.20952","article-title":"Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine","volume":"82","author":"Richardson","year":"2007","journal-title":"Am J Hematol"},{"key":"2019111703545845100_B51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/10428190290021425","article-title":"Response of CD30+ large cell lymphoma of skin to bexarotene","volume":"43","author":"Keun","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2019111703545845100_B54","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1524-4725.1995.tb00513.x","article-title":"Etretinate as an effective adjunctive therapy for recalcitrant palmar\/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis","volume":"21","author":"Lim","year":"1995","journal-title":"Dermatol Surg"},{"key":"2019111703545845100_B56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B58","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"2019111703545845100_B59","first-page":"290","article-title":"Adverse effects of large doses of vitamin A and retinoids","volume":"10","author":"Olson","year":"1983","journal-title":"Semin Oncol"},{"key":"2019111703545845100_B60","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111703545845100_B61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"2019111703545845100_B62","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte.A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"key":"2019111703545845100_B63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B64","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/thy.1997.7.891","article-title":"Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature","volume":"7","author":"Koh","year":"1997","journal-title":"Thyroid"},{"key":"2019111703545845100_B65","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703545845100_B66","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1186\/1471-2210-10-15","article-title":"Pharmacokinetic and pharmacodynamic comparison of two \u201cpegylated\u201d interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study","volume":"10","author":"Garc\u00eda-Garc\u00eda","year":"2010","journal-title":"BMC Pharmacol"},{"key":"2019111703545845100_B67","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"2019111703545845100_B68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3816\/CLM.2006.n.063","article-title":"High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome","volume":"7","author":"Richardson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B70","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","article-title":"Complete remissions in psoralen and UV-A (PUVA;-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA","volume":"129","author":"Mostow","year":"1993","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jnci\/84.2.119","article-title":"Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion","volume":"84","author":"Kuzel","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"2019111703545845100_B73","first-page":"17","article-title":"Interferon alfa 2a combined with etretinate: effective in the treatment of mycosis fungoides","volume":"9","author":"Braather","year":"1987","journal-title":"Retinoids Today Tomorrow"},{"key":"2019111703545845100_B74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B75","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-4362.1993.tb01458.x","article-title":"Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides","volume":"32","author":"Altomare","year":"1993","journal-title":"Intl J Dermatol"},{"key":"2019111703545845100_B76","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"2019111703545845100_B77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/cbr.1996.11.21","article-title":"Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma","volume":"11","author":"Avil\u00e9s","year":"1996","journal-title":"Cancer Biother Radiopharm"},{"key":"2019111703545845100_B78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and S\u00e9zary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"issue":"9","key":"2019111703545845100_B79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"key":"2019111703545845100_B80","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archdermatol.2010.376","article-title":"Reduction of Fas\/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma","volume":"147","author":"Wu","year":"2011","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B81","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2019111703545845100_B82","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/BF02579931","article-title":"Treatment of mycosis fungoides by recombinant leukocyte alpha-A interferon and vinblastine","volume":"111","author":"Scheulen","year":"1986","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019111703545845100_B83","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B84","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B85","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2\u2032-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B86","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"2019111703545845100_B87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2\u2032-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"2019111703545845100_B88","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies: a phase II trial of the EORTC. Leukemia Cooperative Group","volume":"10","author":"Ho","year":"1999","journal-title":"Ann Oncol"},{"key":"2019111703545845100_B89","first-page":"37","article-title":"Pentostatin treatment of cutaneous T-cell lymphoma","volume":"14","author":"Dearden","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"2019111703545845100_B90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2019111703545845100_B91","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2133.1996.tb07852.x","article-title":"A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-gamma and has been in complete remission for more than 6 years","volume":"134","author":"Horikoshi","year":"1996","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B92","first-page":"85","article-title":"Photopheresis: clinical application and mechanism of action","volume":"4","author":"Rook","year":"1999","journal-title":"JID Symp Proc"},{"key":"2019111703545845100_B93","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaad.2008.11.889","article-title":"A novel regimen of vorinostat with interferon gamma for refractory S\u00e9zary syndrome","volume":"61","author":"Gardner","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B94","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","article-title":"High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response","volume":"147","author":"Raphael","year":"2011","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B95","first-page":"547","article-title":"Beta interferon in the treatment of mycosis fungoides","volume":"73","author":"Zinzani","year":"1988","journal-title":"Haematologica"},{"key":"2019111703545845100_B96","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by S\u00e9zary syndrome patients: cytokine secretion pattern resembles murine Th2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0008-8749(92)90011-D","article-title":"Regulation of human cytolytic lymphocyte responses by interleukin-12","volume":"143","author":"Gately","year":"1992","journal-title":"Cell Immunol"},{"key":"2019111703545845100_B98","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"2019111703545845100_B99","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B100","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","article-title":"Histone deacetylase inhibitors: discovery and development as anticancer agents","volume":"14","author":"Marks","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"2019111703545845100_B101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase II Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-cell Lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"2019111703545845100_B102","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.bjc.6603465","article-title":"Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Duvic","year":"2006","journal-title":"Br J Cancer"},{"key":"2019111703545845100_B103","first-page":"17","article-title":"Trends in the treatment of cutaneous T-cell Lymphoma - critical evaluation and perspectives on vorinostat","volume":"2021","author":"Rangwala","year":"2012","journal-title":"Blood Lymph Cancer Target Ther"},{"key":"2019111703545845100_B104","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"key":"2019111703545845100_B105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J Mol Biol"},{"key":"2019111703545845100_B106","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","article-title":"Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines","volume":"33","author":"Sakajiri","year":"2005","journal-title":"Exp Hematol"},{"key":"2019111703545845100_B107","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B108","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ijc.21939","article-title":"The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L\/TRAIL","volume":"119","author":"Butler","year":"2006","journal-title":"Int J Cancer"},{"key":"2019111703545845100_B109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.21824","article-title":"SAHA-sensitized prostate cancer cells to TNF alpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis","volume":"119","author":"Lakshmikanthan","year":"2006","journal-title":"Int J Cancer"},{"key":"2019111703545845100_B110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"2019111703545845100_B111","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"2019111703545845100_B112","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","article-title":"Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\/Bcl-XL, c-Jun, and p21CIP1, but independent of p53","volume":"18","author":"Vrana","year":"1999","journal-title":"Oncogene"},{"key":"2019111703545845100_B113","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6603464","article-title":"Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma","volume":"95","author":"O'Connor","year":"2006","journal-title":"Br J Cancer"},{"key":"2019111703545845100_B114","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cc.4.4.1564","article-title":"Histone deacetylase inhibitors in programmed cell death and cancer therapy","volume":"4","author":"Marks","year":"2005","journal-title":"Cell Cycle"},{"key":"2019111703545845100_B115","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"2019111703545845100_B116","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1476-5381.2010.01188.x","article-title":"The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells","volume":"162","author":"Tiffon","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2019111703545845100_B117","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B118","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"A phase IIb multicenter trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with persistent, progressive, or treatment refractory mycosis fungoides or Sezary syndrome subtypes of cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"2019111703545845100_B119","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clinical Cancer Res"},{"key":"2019111703545845100_B120","first-page":"110","article-title":"Romidepsin (depsipeptide) induces clinically signficant responses in treatment-refractory CTCL: an international study","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"2019111703545845100_B121","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B122","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-Cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B123","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"2019111703545845100_B124","first-page":"614","volume-title":"Hematopoietic stem cell therapy","author":"Marcellus","year":"2000"},{"key":"2019111703545845100_B125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/sj.bmt.1700710","article-title":"Prevention and treatment of acute GVHD: the old and the new: a report from the Eastern Cooperative Oncology group (BCOG)","volume":"19","author":"Lazarus","year":"1997","journal-title":"Bone Marrow Transpl"},{"key":"2019111703545845100_B126","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy","volume":"316","author":"Edelson","year":"1987","journal-title":"N Eng J Med"},{"key":"2019111703545845100_B127","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/jid.1962.106","article-title":"The presently known distributions of furocoumarins (psoralens) in plants","volume":"39","author":"Pathak","year":"1962","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2141.1999.01773.x","article-title":"ECP induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and GVHD patients","volume":"107","author":"Bladon","year":"1999","journal-title":"Brit J Haematol"},{"key":"2019111703545845100_B129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/292060a0","article-title":"Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein","volume":"292","author":"Ben-Nun","year":"1981","journal-title":"Nature"},{"key":"2019111703545845100_B130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1523-1747.ep12329711","article-title":"Apoptosis induction by ultraviolet light A and photochemotherapy in coetaneous T-cell lymphoma: relevance to mechanism of therapeutic action","volume":"107","author":"Yoo","year":"1996","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B131","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0041-1345(00)00966-0","article-title":"Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis","volume":"32","author":"Tambur","year":"2000","journal-title":"Transplant Proc"},{"key":"2019111703545845100_B132","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/32183","article-title":"Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLS","volume":"392","author":"Albert","year":"1998","journal-title":"Nature"},{"key":"2019111703545845100_B133","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-11-125542","article-title":"Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells","volume":"112","author":"Gatza","year":"2008","journal-title":"Blood"},{"key":"2019111703545845100_B134","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111755","article-title":"Extracorporeal Photochemotherapy as a challenging treatment for cutaneous T-cell lymphoma, acute and chronic graft-versus-host disease, organ rejection and T-lymphocyte-mediated autoimmune diseases","volume":"35","author":"Perseghin","year":"2008","journal-title":"Transfus Med Hemother"},{"key":"2019111703545845100_B135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2008.05.038","article-title":"Extracorporeal photopheresis for the treatment of S\u00e9zary syndrome using a novel treatment protocol","volume":"59","author":"Arulogun","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B136","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/jid.2013.142","article-title":"Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease","volume":"133","author":"Shiue","year":"2013","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B137","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(18)30062-5","article-title":"Photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Lim","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703545845100_B138","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mjd.2000.104852","article-title":"Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution","volume":"43","author":"Bisaccia","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B139","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-4362.1991.tb04795.x","article-title":"Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma: complexity of objective evaluation","volume":"30","author":"Oziemski","year":"1991","journal-title":"Int J Dermatol"},{"key":"2019111703545845100_B140","first-page":"567","article-title":"Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T cell lymphoma (CTCL)","volume":"102","author":"Koh","year":"1994","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B141","first-page":"629","article-title":"Photopheresis therapy of cutaneous T cell lymphoma: the Yale-New Haven Hospital experience","volume":"62","author":"Heald","year":"1989","journal-title":"Yale J Biol Med"},{"key":"2019111703545845100_B142","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0190-9622(96)90683-0","article-title":"Photopheresis therapy for cutaneous T-cell lymphoma","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B143","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0190-9622(92)70246-C","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"27","author":"Zic","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B144","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0190-9622(90)70312-6","article-title":"Photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"23","author":"Armus","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF00371732","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: the Dusseldorf and Munich experience","volume":"287","author":"Prinz","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"2019111703545845100_B146","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0781.1999.tb00077.x","article-title":"Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience","volume":"15","author":"Jiang","year":"1999","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2019111703545845100_B147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0190-9622(98)70597-3","article-title":"Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma","volume":"38","author":"Vonderheid","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B148","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s001050050387","article-title":"Therapeutische Erfahrungen mit der Extracorporalen Photopherese","volume":"47","author":"Owsianowski","year":"1996","journal-title":"Hautarzt"},{"key":"2019111703545845100_B149","first-page":"294","article-title":"Applicazione della fotoferesis nella terapia di malattie oncologiche ed autiommuni: the application of photopheresis in the therapy of cancerous and autoimmune disease","volume":"82","author":"Dall'Amico","year":"1991","journal-title":"Recenti Prog Med"},{"key":"2019111703545845100_B150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/039139880002300109","article-title":"Photopheresis in cutaneous T-cell lymphoma: five-year experience","volume":"23","author":"Crovetti","year":"2000","journal-title":"Int J Artif Organs"},{"key":"2019111703545845100_B151","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0926-9959(97)00045-7","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy","volume":"9","author":"Konstantinow","year":"1997","journal-title":"J Europ Acad Derm Vener"},{"key":"2019111703545845100_B152","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(05)62067-3","article-title":"Extracorporeal photopheresis in S\u00e9zary syndrome","volume":"350","author":"Russell-Jones","year":"1997","journal-title":"Lancet"},{"key":"2019111703545845100_B153","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archderm.135.8.995-a","article-title":"Effectiveness of photopheresis in Sezary syndrome","volume":"135","author":"Stevens","year":"1999","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B154","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/archderm.135.5.600","article-title":"S\u00e9zary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis","volume":"135","author":"Edelson","year":"1999","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"key":"2019111703545845100_B156","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0190-9622(96)90118-8","article-title":"Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy","volume":"35","author":"Zic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B157","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-642-78771-3_32","article-title":"Extracorporeal photopheresis: a new approach for the treatment of cutaneous T cell lymphomas","volume":"139","author":"Gollnick","year":"1995","journal-title":"Recent Results Cancer Res"},{"key":"2019111703545845100_B158","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy","volume":"27","author":"Heald","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B159","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archderm.134.8.1001","article-title":"Extracorporeal photopheresis in S\u00e9zary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone","volume":"134","author":"Fraser-Andrews","year":"1998","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B161","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CLM.2008.n.005","article-title":"Cutaneous gamma\/delta T-cell lymphoma treated with radiation and denileukin diftitox","volume":"8","author":"Vidulich","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B162","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"key":"2019111703545845100_B163","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2133.2005.06857.x","article-title":"Evidence-based practice of photopheresis 1987-2001: a report of a workshop ofthe British photodermatology group and the U.K. skin lymphoma group","volume":"154","author":"McKenna","year":"2006","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B164","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0190-9622(97)80226-5","article-title":"Proceedings of the international consensus conference on cutaneous T-cell lymphoma (CTCL) treatment recommendations: Boston, Massachusetts, Oct 1 and 2, 1994","volume":"36","author":"Demierre","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B165","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0889-8588(03)00106-0","article-title":"Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow","volume":"17","author":"Girardi","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703545845100_B166","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1473-0502(02)00103-9","article-title":"Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma","volume":"28","author":"Knobler","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"2019111703545845100_B167","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archderm.138.10.1347","article-title":"Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of S\u00e9zary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B168","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1034\/j.1600-0781.2002.02762.x","article-title":"Extracorporeal photochemotherapy: the Columbia presbyterian experience","volume":"18","author":"Knobler","year":"2002","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2019111703545845100_B169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0781.2007.00300.x","article-title":"Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma","volume":"23","author":"Miller","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2019111703545845100_B170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"2019111703545845100_B171","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2567.1997.00325.x","article-title":"Extracorporeal photochemotherapy restores Th1\/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma","volume":"92","author":"Di Renzo","year":"1997","journal-title":"Immunology"},{"key":"2019111703545845100_B172","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"2019111703545845100_B173","first-page":"1197","article-title":"Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy","volume":"7","author":"Wollina","year":"2000","journal-title":"Oncol Rep"},{"key":"2019111703545845100_B174","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2133.2000.03857.x","article-title":"Extracorporeal photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma","volume":"143","author":"Rubegni","year":"2000","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.2001.tb03726.x","article-title":"Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial","volume":"941","author":"Wollina","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"2019111703545845100_B176","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","article-title":"Multicenter photopheresis intervention trial in early-stage mycosis fungoides","volume":"11","author":"Talpur","year":"2011","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2019111703545845100_B177","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/archderm.1991.01680090099012","article-title":"Combined therapy for S\u00e9zary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy: clinical, molecular, and immunologic observations","volume":"127","author":"Rook","year":"1991","journal-title":"Arch Dermatol"},{"key":"2019111703545845100_B178","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1067\/mjd.2000.105163","article-title":"Evidence is lacking for a synergistic or additive effect of combination extracorporeal photopheresis with interferon alfa for cutaneous T-cell lymphoma","volume":"42","author":"Zackheim","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B179","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111703545845100_B180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.2004.05712.x","article-title":"Treatment of advanced mycosis fungoides\/S\u00e9zary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy","volume":"150","author":"Quaglino","year":"2004","journal-title":"Br J Dermatol"},{"key":"2019111703545845100_B181","doi-asserted-by":"crossref","first-page":"698a","DOI":"10.1182\/blood.V108.11.2467.2467","article-title":"Oral forodesine (BCX-1777) is clinically active in refractory cutaneous t-cell lymphoma: results of a phase I\/II study oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"2019111703545845100_B182","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/14796694.4.4.457","article-title":"Optimizing denileukin diftitox (Ontak) therapy","author":"Duvic","year":"2008","journal-title":"Future Oncol"},{"key":"2019111703545845100_B183","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B184","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1096-8652(199805)58:1<87::AID-AJH18>3.0.CO;2-2","article-title":"DAB389IL2 diphtheria fusion toxin produces responses in tumor stage cutaneous T-cell lymphoma","volume":"58","author":"Duvic","year":"1998","journal-title":"Am J Hematol"},{"key":"2019111703545845100_B185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2019111703545845100_B186","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3816\/CLM.2006.n.059","article-title":"Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox","volume":"7","author":"Chin","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B187","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"2019111703545845100_B188","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B189","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2000.n.009","article-title":"DAB(389;IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymphoma"},{"key":"2019111703545845100_B190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389;IL-2 (denileukin diftitox, ONTAK; in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B191","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10428190210183","article-title":"Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)","volume":"43","author":"Talpur","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2019111703545845100_B192","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"2019111703545845100_B193","first-page":"1","article-title":"Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory S\u00e9zary syndrome","author":"Roch","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2019111703545845100_B194","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111703545845100_B195","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"2019111703545845100_B196","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol"},{"key":"2019111703545845100_B197","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11899-011-0096-8","article-title":"CD30+ neoplasms of the skin","volume":"6","author":"Duvic","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"2019111703545845100_B198","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B199","doi-asserted-by":"crossref","first-page":"768a","DOI":"10.1182\/blood.V108.11.2718.2718","article-title":"SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)","volume":"108","author":"Forero-Torres","year":"2006","journal-title":"Blood"},{"key":"2019111703545845100_B200","article-title":"Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis","author":"Duvic","journal-title":"J Clin. Oncol"},{"key":"2019111703545845100_B201","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","author":"Kim","journal-title":"J Clin. Oncol"},{"key":"2019111703545845100_B202","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1346-8138.12852","article-title":"CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis","volume":"42","author":"Sugaya","year":"2015","journal-title":"J Dermatol"},{"issue":"4","key":"2019111703545845100_B203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas","volume":"106","author":"Utsunomiya","year":"2015","journal-title":"Cancer Sci"},{"key":"2019111703545845100_B204","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"2019111703545845100_B205","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2019111703545845100_B206","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"2019111703545845100_B207","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"2019111703545845100_B208","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111703545845100_B209","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00001622-200111000-00015","article-title":"Gemcitabine in hematologic malignancies","volume":"13","author":"Nabhan","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"2019111703545845100_B210","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"2019111703545845100_B211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111703545845100_B212","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B213","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"2019111703545845100_B214","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V61.2.279.bloodjournal612279","article-title":"An investigation of 2\u2032-deoxycoformycin in the treatment of cutaneous T-cell lymphoma","volume":"61","author":"Grever","year":"1983","journal-title":"Blood"},{"key":"2019111703545845100_B216","first-page":"58","article-title":"Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies","volume":"27","author":"Foss","year":"2000","journal-title":"Semin Oncol"},{"key":"2019111703545845100_B217","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B218","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.2830380320","article-title":"Cardiac complications observed in elderly patients following 2\u2032deoxycoformycin therapy","volume":"38","author":"Grem","year":"1991","journal-title":"Am J Hematol"},{"key":"2019111703545845100_B219","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2001.tb03727.x","article-title":"Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up","volume":"941","author":"Wollina","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"2019111703545845100_B220","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.3816\/CLM.2007.s.018","article-title":"Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience","volume":"7","author":"Chanan-Khan","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111703545845100_B221","first-page":"869","article-title":"Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study","volume":"64","author":"Ryan","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"2019111703545845100_B222","first-page":"891","article-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes","volume":"52","author":"Gabizon","year":"1992","journal-title":"Cancer Res"},{"key":"2019111703545845100_B223","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"2019111703545845100_B224","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","article-title":"The treatment of S\u00e9zary syndrome","volume":"10","author":"Winkelmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"2019111703545845100_B225","first-page":"167","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV mycosis fungoides","volume":"66","author":"Tirelli","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"2019111703545845100_B226","first-page":"647","article-title":"Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study","volume":"63","author":"Grozea","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2019111703545845100_B227","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1988.6.7.1177","article-title":"Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up","volume":"6","author":"Hallahan","year":"1988","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B228","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1097-0142(19861215)58:12<2611::AID-CNCR2820581210>3.0.CO;2-W","article-title":"Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M)","volume":"58","author":"Zakem","year":"1986","journal-title":"Cancer"},{"key":"2019111703545845100_B229","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111703545845100_B230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with S\u00e9zary syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111703545845100_B231","first-page":"S46","article-title":"Increased levels of CD4+25 high regulatory T cells in patients with cutaneous T-cell lymphoma after extracorporeal photopheresis","volume":"129","author":"Shiue","year":"2009","journal-title":"J Investig Dermatol"},{"key":"2019111703545845100_B232","first-page":"103","article-title":"Dendritic cells and cutaneous T-cell lymphomas","volume":"146","author":"Ni","year":"2011","journal-title":"G Ital Derm Venereol"},{"key":"2019111703545845100_B233","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Pinter-Brown LC2, Foss FM3, et al","year":"2015","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/529\/1250718\/bep00115000529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/529\/1250718\/bep00115000529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:15:22Z","timestamp":1718781322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/529\/20683\/Choosing-a-systemic-treatment-for-advanced-stage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":233,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.529","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}